What is Renerva?
Renerva, Inc. is at the forefront of developing advanced surgical solutions designed to enhance healing following nerve injuries. The company's primary focus is on its investigational PNM-CAP device, which has achieved a critical milestone with FDA IDE approval for initiating first-in-human clinical trials. While currently not available for commercial use, Renerva's commitment lies in pioneering advancements in nerve recovery and mitigating nerve pain for individuals affected by such conditions. The company's strategic positioning in the medical device sector is further solidified by its recent substantial capital infusion.
How much funding has Renerva raised?
Renerva has raised a total of $408K across 2 funding rounds:
Debt
$83K
Private Equity
$325K
Debt (2021): $83K with participation from PPP
Private Equity (2025): $325K, investors not publicly disclosed
Key Investors in Renerva
PPP
Public-Private Partnership
What's next for Renerva?
With the recent influx of $325K in a major strategic investment, Renerva is poised for significant operational expansion and the advancement of its clinical trial pipeline. This large-scale, late-stage funding indicates strong investor confidence in the company's technology and its potential to address unmet needs in nerve injury treatment. The capital is anticipated to fuel further research and development, scale manufacturing capabilities, and support regulatory pathways toward eventual commercialization. Renerva's trajectory suggests a focus on achieving key clinical endpoints and preparing for market entry.
See full Renerva company page
